PNC-27
Also known as: PNC27 · p53-penetratin chimera · MDM-2 targeting peptide
A chimeric anticancer peptide fusing a p53 MDM-2 binding domain with a penetratin membrane-translocation region. Selectively forms pores in cancer cell membranes that overexpress HDM-2 (human MDM-2 oncoprotein), causing rapid membranolysis and cancer cell death while sparing normal cells.
What is PNC-27? A chimeric anticancer peptide fusing a p53 MDM-2 binding domain with a penetratin membrane-translocation region. Selectively forms pores in cancer cell membranes that overexpress HDM-2 (human MDM-2 oncoprotein), causing rapid membranolysis and cancer cell death while sparing normal cells.
How does PNC-27 work? PNC-27 fuses two functional domains: a p53 residues 12-26 sequence (which binds MDM-2/HDM-2) with a penetratin cell-penetrating peptide. HDM-2 is overexpressed at cancer cell surface membranes. PNC-27 binds HDM-2, and the penetratin domain inserts into the lipid bilayer forming pores causing membranolysis within minutes — a non-apoptotic cancer cell killing mechanism.
Benefits of PNC-27: Selective cancer cell membranolysis via HDM-2 binding; Spares normal cells that do not overexpress HDM-2; Rapid cell death mechanism; Active against leukemia, melanoma, pancreatic, breast cancer; Non-apoptotic mechanism — may work in chemo-resistant cancers; Synergy potential with standard chemotherapy
PNC-27 dosage: CAUTION: Anticancer research compound exclusively. Not for human self-administration. In vitro and in vivo research use only.
Research status: Research Only
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/pnc-27
Mechanism of Action
PNC-27 fuses two functional domains: a p53 residues 12-26 sequence (which binds MDM-2/HDM-2) with a penetratin cell-penetrating peptide. HDM-2 is overexpressed at cancer cell surface membranes. PNC-27 binds HDM-2, and the penetratin domain inserts into the lipid bilayer forming pores causing membranolysis within minutes — a non-apoptotic cancer cell killing mechanism.
Benefits
- Selective cancer cell membranolysis via HDM-2 binding
- Spares normal cells that do not overexpress HDM-2
- Rapid cell death mechanism
- Active against leukemia, melanoma, pancreatic, breast cancer
- Non-apoptotic mechanism — may work in chemo-resistant cancers
- Synergy potential with standard chemotherapy
Side Effects & Risks
- Research compound only — NOT for self-administration
- Potential off-target membranolytic effects at high doses
- Systemic safety not established in humans
- Injection site necrosis risk at wrong concentration
Where to Buy PNC-27
1 option across 1 vendor · Sorted cheapest first · All include direct product link
From
$245.00
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C (lyophilized)
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Preclinical Research & Reviews1
PNC-27 kills cancer cells by selective membranolysis via HDM-2
PNC-27 caused selective membranolysis and rapid death in HDM-2 overexpressing cancer cells while completely sparing normal cells. Active against pancreatic, leukemia, melanoma, and breast cancer lines within minutes.
Speed
Membranolysis within minutes
Mechanism
Pore formation via penetratin domain after HDM-2 binding
Selectivity
100% selective for HDM-2 overexpressing cancer cells
Cancers Tested
Pancreatic, leukemia, melanoma, breast cancer cell lines
Research Protocol
- Frequency
- Research protocol only
- Cycle
- Research protocol only
- Routes
- subcutaneous injectionintravenous injection
- Notes
- CAUTION: Anticancer research compound exclusively. Not for human self-administration. In vitro and in vivo research use only.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
Chemical Properties
- CAS Number
- 1159861-00-3
- Mol. Weight
- 4,031.73 Da
- Formula
- C188H293N53O44S
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About PNC-27
What is PNC-27?▾
A chimeric anticancer peptide fusing a p53 MDM-2 binding domain with a penetratin membrane-translocation region. Selectively forms pores in cancer cell membranes that overexpress HDM-2 (human MDM-2 oncoprotein), causing rapid membranolysis and cancer cell death while sparing normal cells.
What are the benefits of PNC-27?▾
Selective cancer cell membranolysis via HDM-2 binding
What are the benefits of PNC-27?▾
Spares normal cells that do not overexpress HDM-2
What are the side effects of PNC-27?▾
Research compound only — NOT for self-administration
What is the recommended dosage for PNC-27?▾
CAUTION: Anticancer research compound exclusively. Not for human self-administration. In vitro and in vivo research use only.
How long should a PNC-27 cycle last?▾
Research protocol only
More Experimental Peptides
View all Experimental peptides →Adipotide
FTPP
A highly experimental proapoptotic peptide that selectively destroys the blood supply to white adipose tissue. Dramatic fat loss in animal models but significant renal toxicity concerns.
Macimorelin
AEZS-130
An orally active ghrelin receptor agonist FDA-approved as a diagnostic test for adult growth hormone deficiency. Provides a convenient oral GH stimulation test.